Skip to main content

Biodexa Pharmaceuticals Plc

BDRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001643918

No open-market purchases or sales by Biodexa Pharmaceuticals Plc insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $48.1K in total; no superinvestor holds it.

Holders of 5% or more of BDRX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Biodexa Pharmaceuticals Plc, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of BDRX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Armistice Capital, LLC13G/A9.99%26.2K shares0.00 ppfrom 9.99%Feb 14, 20235 filingsAug 14, 2026SEC
Sabby Management, LLC13G9.90%217.6K sharesNewJan 20, 20261 filingJan 20, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

23 Schedule 13D and 13G filings on Biodexa Pharmaceuticals Plc, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on BDRX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 202610:03 AM ETArmistice Capital, LLCand 1 other13G/A9.99%26.2K shares0.00 ppfrom 9.99%Jun 30, 2026SEC
May 15, 202611:08 AM ETArmistice Capital, LLCand 1 other13G/A9.99%188.0K shares0.00 ppfrom 9.99%Mar 31, 2026SEC
Feb 17, 20269:55 PM ETArmistice Capital, LLCand 1 other13G9.99%283.5K shares–Dec 31, 2025SEC
Jan 20, 20261:49 PM ETSabby Management, LLCand 2 others13G9.90%217.6K sharesNewDec 31, 2025SEC
Nov 14, 20254:18 PM ETC/M Capital Partners, LPand 7 others13G/A0.00%0 shares−6.80 ppfrom 6.80%Below 5%Jun 30, 2025SEC
May 28, 20255:59 PM ETC/M Capital Partners, LPand 7 others13G6.80%1.75B shares+6.80 ppfrom 0.00%May 20, 2025SEC
Feb 18, 20254:30 PM ETC/M Capital Partners, LPand 3 others13G0.00%0 sharesNewBelow 5%Feb 10, 2025SEC
Nov 20, 2024Brio Capital Master Fund Ltd.13G/AOld format–––SEC
Nov 14, 2024Iroquois Capital Management, LLC13G/AOld format–––SEC
Nov 12, 2024Bigger Capital, LLC13G/AOld format–––SEC
Nov 7, 2024Cavalry Fund I LP13G/AOld format–––SEC
Aug 8, 2024Iroquois Capital Management, LLC13GOld format–New–SEC
Jul 23, 2024Brio Capital Master Fund Ltd.13GOld format–New–SEC
Feb 14, 2024Ionic Ventures, LLC13G/AOld format–––SEC
Feb 14, 2024Armistice Capital, LLC13G/AOld format–––SEC
Feb 14, 2024CVI Investments, Inc.13G/AOld format–––SEC
Feb 13, 2024Cavalry Fund I LP13G/AOld format–––SEC
Feb 12, 2024Bigger Capital, LLC13GOld format–New–SEC
Jan 8, 2024Mercer Street Global Opportunity Fund, LLC13GOld format–New–SEC
Dec 28, 2023Cavalry Fund I LP13GOld format–New–SEC
Mar 6, 2023Ionic Ventures, LLC13GOld format–New–SEC
Feb 21, 2023CVI Investments, Inc.13GOld format–New–SEC
Feb 14, 2023Armistice Capital, LLC13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Biodexa Pharmaceuticals Plc shares.

No Form 144 notices for Biodexa Pharmaceuticals Plc are on file.